



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.

Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

[Back to PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

[Back to PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Refine Search

Search Results -

| Terms | Documents |
|---------------------|-----------|
| L7 and @pd<20030822 | 34 |

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L8

Refine Search

Recall Text  Clear Interrupt

Search History

DATE: Friday, June 16, 2006 [Printable Copy](#) [Create Case](#)

| Set Name | Query | Hit Count | Set Name |
|--------------------------------------------------------|------------------------------------------------|-----------|------------|
| side by side | | | result set |
| DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR | | | |
| L8 | L7 and @pd<20030822 | 34 | L8 |
| L7 | L6 and ((HFA adj 227) or (heptafluoropropane)) | 136 | L7 |
| L6 | (mometasone adj furoate) | 1150 | L6 |
| DB=USPT; PLUR=YES; OP=OR | | | |
| L5 | 6365581.pn. | 1 | L5 |
| DB=PGPB,USPT; PLUR=YES; OP=OR | | | |
| L4 | L3 and mometasone | 30 | L4 |
| L3 | Joel near Sequeira | 51 | L3 |
| L2 | Stefan near Sharpe | 7 | L2 |
| DB=PGPB; PLUR=YES; OP=OR | | | |
| L1 | 20050147565 | 1 | L1 |

END OF SEARCH HISTORY



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
[Sign In] [Req]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

B

Search PubMed

for mometasone furoate and HFA-227

Go

Clear

Save S

Limits Preview/Index History Clipboard Details

1: Clin Ther. 2000 Dec;22(12):1483-93.

Related Articles, Links

ELSEVIER
Full Text Article

Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler.

Pickering H, Pitcairn GR, Hirst PH, Bacon PR, Newman SP, Affrime MB, Marino M.

Pharmaceutical Profiles Ltd, Nottingham, United Kingdom.

BACKGROUND: A new inhaled suspension formulation of mometasone furoate (MF), a potent corticosteroid with minimal systemic availability, has been developed for the treatment of asthma. This formulation is delivered by metered-dose inhaler (MDI) using the nonchlorofluorocarbon propellant hydrofluoroalkane 227 (HFA-227). **OBJECTIVE:** The primary goal of this study was to determine the respiratory tract deposition of this formulation of MF. A secondary objective was to measure plasma concentrations of MF and a putative metabolite, 6-X-OH MF, to determine the systemic exposure to corticosteroid. **METHODS:** This was a single-dose, open-label study in which 200 microg of technetium 99m (99mTc)-radiolabeled MF was administered to patients with asthma. Gamma scintigraphy was used to quantify lung, oropharyngeal, stomach, and MDI mouthpiece deposition patterns of MF. **RESULTS:** Eleven patients, aged 21 to 47 years, with a history of asthma were enrolled in and completed the study. The mean (+/- SD) whole lung deposition of MF was 13.9%+/-5.7% of the metered (ex-valve) dose. The central lung zone received 5.3%+/-2.8% of the dose; the intermediate zone received 4.7%+/-1.9%; and peripheral lung deposition was 4.0%+/-1.5%. The mean (+/- SD) ratio of peripheral to central lung deposition was 0.8+/-0.2. Oropharyngeal deposition was 79.1%+/-8.7% of the ex-valve dose, with 6.3%+/-7.8% deposited on the MDI mouthpiece and 0.7%+/-0.5% exhaled. The majority of plasma samples taken for analysis of MF and 6-13-OH MF concentrations were below the limit of quantification (50 pg/mL) in all patients after inhalation of 200 microg 99mTc-labeled MF. **CONCLUSION:** The lung deposition of MF when administered via HFA-227 MDI is comparable to the 10 to 20% lung deposition seen with other corticosteroid suspension formulations administered by MDI that have demonstrated effectiveness in the treatment of asthma.

Publication Types:

- Clinical Trial
- Historical Article